Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Acer Therapeutics Inc.ACER · Entity 108116 | Director | March 14, 2023 | March 16, 2023 |
| Akebia Therapeutics, Inc.AKBA · Entity 6105 | SVP, CFO & Treasurer | February 28, 2020 | March 02, 2020 |
| Candel Therapeutics, Inc.CADL · Entity 4969 | Chief Financial Officer | November 28, 2023 | November 30, 2023 |
| TScan Therapeutics, Inc.TCRX · Entity 7255 | Chief Financial Officer | January 20, 2026 | January 22, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Acer Therapeutics Inc.
Report date March 14, 2023 · Filed March 16, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.67 · Expires 2033-03-14 | Direct | 20,000 |
Reported balance
After 2023-03-14 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-03-14 · Grant · Acquired 20,000 · Balance 20,000 F1: The option, which is made as part of the Issuer's 2023 annual compensation cycle, vests and becomes exercisable in full on March 14, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: The option, which is made as part of the Issuer's 2023 annual compensation cycle, vests and becomes exercisable in full on March 14, 2024.
Akebia Therapeutics, Inc.
Report date February 28, 2020 · Filed March 02, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 151,618 |
Reported balance
After 2020-02-28 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2020-02-28 · Grant · Acquired 30,000 · Balance 151,618 F1: The restricted stock units were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended. One third of the restricted stock units will vest on each of the first, second and third anniversaries of the grant date. F2: Includes 1,500 shares of the Issuer's common stock purchased on June 28, 2019 and 1,500 shares of the Issuer's common stock purchased on December 31, 2019, each under the Issuer's Amended and Restated 2014 Employee Stock Purchase Plan. |
| Common StockSEC Table I · non-derivative | Direct | 144,642 |
Reported balance
After 2020-02-28 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2020-02-28 · Sale · Disposed 6,976 · Balance 144,642 F3: This sale was made to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on February 28, 2019. |
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.87 · Expires 2030-02-28 | Direct | 45,000 |
Reported balance
After 2020-02-28 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-02-28 · Grant · Acquired 45,000 · Balance 45,000 F4: The options were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended. The options will vest over four years: 25% of the options will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: The restricted stock units were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended. One third of the restricted stock units will vest on each of the first, second and third anniversaries of the grant date.
F2: Includes 1,500 shares of the Issuer's common stock purchased on June 28, 2019 and 1,500 shares of the Issuer's common stock purchased on December 31, 2019, each under the Issuer's Amended and Restated 2014 Employee Stock Purchase Plan.
F3: This sale was made to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on February 28, 2019.
F4: The options were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended. The options will vest over four years: 25% of the options will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter.
Candel Therapeutics, Inc.
Report date November 28, 2023 · Filed November 30, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 202,009 |
Reported balance
After 2023-11-28 transaction · row 1
1 source rowRow 1 · 2023-11-28 · Tax withholding · Disposed 20,153 · Balance 202,009 F1: These shares were withheld by the Issuer to satisfy tax withholding obligations associated with the vesting and settlement of restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares were withheld by the Issuer to satisfy tax withholding obligations associated with the vesting and settlement of restricted stock units.
TScan Therapeutics, Inc.
Report date January 20, 2026 · Filed January 22, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.12 · Expires 2036-01-20 | Direct | 350,000 |
Reported balance
After 2026-01-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-20 · Grant · Acquired 350,000 · Balance 350,000 F1: The shares subject to this option shall vest and become exercisable with respect to 25% of the shares on the one-year anniversary of January 20, 2026, with the balance vesting thereafter in equal monthly installments over the next 36 months, subject to the Reporting Person's continued service to the Issuer on each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to this option shall vest and become exercisable with respect to 25% of the shares on the one-year anniversary of January 20, 2026, with the balance vesting thereafter in equal monthly installments over the next 36 months, subject to the Reporting Person's continued service to the Issuer on each vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 20, 2026 Filed Jan 22, 2026 22:52 UTC | TScan Therapeutics, Inc. TCRX · Entity 7255 | GrantStock Option (Right to Buy) · Derivative | 350,000 | $0.00 Strike: $1.12 | $0.00 |
DisclosureSEC source: 0001193125-26-019729 · ownership.xml · derivative · entry 1 Amello Jason · CIK 0001451805 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 350,000 Underlying: Voting Common Stock · 350,000 shares Expires 2036-01-20 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable with respect to 25% of the shares on the one-year anniversary of January 20, 2026, with the balance vesting thereafter in equal monthly installments over the next 36 months, subject to the Reporting Person's continued service to the Issuer on each vesting date. Read SEC document |
| January 03, 2025 Filed Feb 11, 2025 22:47 UTC | TScan Therapeutics, Inc. TCRX · Entity 7255 | GrantStock Option (Right to Buy) · Derivative | 270,000 | $0.00 Strike: $3.07 | $0.00 |
DisclosureSEC source: 0000950170-25-018120 · ownership.xml · derivative · entry 1 Amello Jason · CIK 0001451805 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 270,000 Underlying: Voting Common Stock · 270,000 shares Expires 2035-01-03 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable with respect to 25% of the shares on the one-year anniversary of January 3, 2025, with the balance vesting thereafter in equal monthly installments over the next 36 months of continuous service to the Issuer. Read SEC document |
| February 01, 2024 Filed Feb 2, 2024 21:21 UTC | TScan Therapeutics, Inc. TCRX · Entity 7255 | GrantStock Option (Right to Buy) · Derivative | 750,000 | $0.00 Strike: $5.15 | $0.00 |
DisclosureSEC source: 0000950170-24-010522 · ownership.xml · derivative · entry 1 Amello Jason · CIK 0001451805 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 750,000 Underlying: Voting Common Stock · 750,000 shares Expires 2034-01-31 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable with respect to 25% of the shares on the one-year anniversary of January 29, 2024, with the balance vesting thereafter in equal monthly installments over the next 36 months of continuous service to the Issuer. Read SEC document |
| November 28, 2023 Filed Nov 30, 2023 17:00 UTC | Candel Therapeutics, Inc. CADL · Entity 4969 | Tax withholdingCommon Stock | 20,153 | $0.90 | $18,137.70 |
DisclosureSEC source: 0001209191-23-056981 · doc4.xml · nonDerivative · entry 1 Amello Jason · CIK 0001451805 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 202,009 F1 · shares: These shares were withheld by the Issuer to satisfy tax withholding obligations associated with the vesting and settlement of restricted stock units. Read SEC document |
| November 26, 2023 Filed Nov 28, 2023 16:30 UTC | Candel Therapeutics, Inc. CADL · Entity 4969 | GrantCommon Stock | 125,717 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-056802 · doc4.xml · nonDerivative · entry 1 Amello Jason · CIK 0001451805 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 222,162 F1 · shares: Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock upon vesting and settlement. 50% of the RSUs shall vest on June 30, 2024, and the remaining 50% on December 31, 2024, in each case subject to the Reporting Person's continued service on such vesting date. Read SEC document |
| April 28, 2023 Filed May 2, 2023 16:45 UTC | Candel Therapeutics, Inc. CADL · Entity 4969 | GrantStock Option (Right to Buy) · Derivative | 90,000 | $0.00 Strike: $1.29 | $0.00 |
DisclosureSEC source: 0001209191-23-026542 · doc4.xml · derivative · entry 1 Amello Jason · CIK 0001451805 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 90,000 shares Expires 2033-04-28 F1 · derivative.exercise_date: This option is subject to time-based vesting. The shares underlying this option shall vest and become exercisable in forty-eight (48) equal monthly installments following April 28, 2023, subject to the Reporting Person's continued service on each vesting date. Read SEC document |
| March 14, 2023 Filed Mar 16, 2023 16:21 UTC | Acer Therapeutics Inc. ACER · Entity 108116 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $1.67 | $0.00 |
DisclosureSEC source: 0001209191-23-019289 · doc4.xml · derivative · entry 1 Amello Jason · CIK 0001451805 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2033-03-14 F1 · derivative.exercise_date: The option, which is made as part of the Issuer's 2023 annual compensation cycle, vests and becomes exercisable in full on March 14, 2024. Read SEC document |
| December 09, 2022 Filed Dec 12, 2022 16:25 UTC | Candel Therapeutics, Inc. CADL · Entity 4969 | PurchaseCommon Stock | 2,468 | $1.93 | $4,763.24 |
DisclosureSEC source: 0001209191-22-060691 · doc4.xml · nonDerivative · entry 2 Amello Jason · CIK 0001451805 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,568 F2 · price: The price in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $1.85 to $2.00. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 08, 2022 Filed Dec 12, 2022 16:25 UTC | Candel Therapeutics, Inc. CADL · Entity 4969 | PurchaseCommon Stock | 3,100 | $1.69 | $5,239.00 |
DisclosureSEC source: 0001209191-22-060691 · doc4.xml · nonDerivative · entry 1 Amello Jason · CIK 0001451805 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,100 F1 · price: The price in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $1.55 to $1.78. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 28, 2022 Filed Nov 30, 2022 18:31 UTC | Candel Therapeutics, Inc. CADL · Entity 4969 | GrantCommon Stock | 90,877 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-037232 · doc4.xml · nonDerivative · entry 1 Amello Jason · CIK 0001451805 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,877 F1 · shares: Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock upon vesting and settlement. 50% of the RSUs shall vest on November 28, 2023, and the remaining 50% on November 28, 2024, in each case subject to the Reporting Person's continued service on such vesting date. Read SEC document |
| September 21, 2022 Filed Sep 23, 2022 16:15 UTC | Candel Therapeutics, Inc. CADL · Entity 4969 | GrantStock Option (Right to Buy) · Derivative | 230,000 | $0.00 Strike: $3.21 | $0.00 |
DisclosureSEC source: 0001209191-22-051131 · doc4.xml · derivative · entry 1 Amello Jason · CIK 0001451805 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 230,000 Underlying: Common Stock · 230,000 shares Expires 2032-09-21 F1 · derivative.exercise_date: 25% of the shares underlying this option shall vest and become exercisable on September 21, 2023, with the remainder vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| January 14, 2022 Filed Jan 19, 2022 16:10 UTC | Acer Therapeutics Inc. ACER · Entity 108116 | GrantStock Option (right to buy) · Derivative | 18,500 | $0.00 Strike: $2.21 | $0.00 |
DisclosureSEC source: 0001209191-22-003701 · doc4.xml · derivative · entry 1 Amello Jason · CIK 0001451805 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,500 Underlying: Common Stock · 18,500 shares Expires 2032-01-14 F1 · derivative.exercise_date: The option vests and becomes exercisable in full on January 14, 2023. Read SEC document |
| January 15, 2021 Filed Jan 20, 2021 16:08 UTC | Acer Therapeutics Inc. ACER · Entity 108116 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $3.85 | $0.00 |
DisclosureSEC source: 0001209191-21-004256 · doc4.xml · derivative · entry 1 Amello Jason · CIK 0001451805 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2031-01-15 F1 · derivative.exercise_date: The option vests and becomes exercisable in full on January 15, 2022. Read SEC document |
| February 28, 2020 Filed Mar 2, 2020 19:27 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantStock Option (Right to buy) · Derivative | 45,000 | $0.00 Strike: $8.87 | $0.00 |
DisclosureSEC source: 0001562180-20-001935 · primarydocument.xml · derivative · entry 3 Amello Jason · CIK 0001451805 · SVP, CFO & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2030-02-28 F4 · derivative.exercise_date: The options were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended. The options will vest over four years: 25% of the options will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter. Read SEC document |
| February 28, 2020 Filed Mar 2, 2020 19:27 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | SaleCommon Stock | 6,976 | $8.70 | $60,691.20 |
DisclosureSEC source: 0001562180-20-001935 · primarydocument.xml · nonDerivative · entry 2 Amello Jason · CIK 0001451805 · SVP, CFO & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,642 F3 · shares: This sale was made to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on February 28, 2019. Read SEC document |
| February 28, 2020 Filed Mar 2, 2020 19:27 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantCommon Stock | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-20-001935 · primarydocument.xml · nonDerivative · entry 1 Amello Jason · CIK 0001451805 · SVP, CFO & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 151,618 F1 · shares: The restricted stock units were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended. One third of the restricted stock units will vest on each of the first, second and third anniversaries of the grant date. F2 · balance_after: Includes 1,500 shares of the Issuer's common stock purchased on June 28, 2019 and 1,500 shares of the Issuer's common stock purchased on December 31, 2019, each under the Issuer's Amended and Restated 2014 Employee Stock Purchase Plan. Read SEC document |
| January 02, 2020 Filed Jan 3, 2020 16:09 UTC | Acer Therapeutics Inc. ACER · Entity 108116 | GrantStock Option (right to buy) · Derivative | 9,000 | $0.00 Strike: $3.79 | $0.00 |
DisclosureSEC source: 0001209191-20-000814 · doc4.xml · derivative · entry 1 Amello Jason · CIK 0001451805 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Stock · 9,000 shares Expires 2030-01-02 F1 · derivative.exercise_date: The option vests and becomes exercisable in full on January 2, 2021. Read SEC document |
| April 11, 2019 Filed Apr 12, 2019 16:00 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | Disposition to issuerCommon Stock | 13,148 | $7.70 | $101,239.60 |
DisclosureSEC source: 0000899243-19-010587 · doc4.xml · nonDerivative · entry 1 Amello Jason · CIK 0001451805 · SVP, CFO & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,618 F1 · shares: The proceeds from the disposition of these shares are to be used by the reporting person to cover tax liabilities associated with previously vested restricted stock units. Read SEC document |
| February 28, 2019 Filed Mar 5, 2019 16:06 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantEmployee Stock Option (Right to buy) · Derivative | 100,000 | $0.00 Strike: $7.28 | $0.00 |
DisclosureSEC source: 0001562180-19-001675 · primarydocument.xml · derivative · entry 2 Amello Jason · CIK 0001451805 · SVP, CFO & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2029-02-28 F3 · derivative.exercise_date: The options were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended. 25% of the options will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter. Read SEC document |
| February 28, 2019 Filed Mar 5, 2019 16:06 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantCommon Stock | 65,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-19-001675 · primarydocument.xml · nonDerivative · entry 1 Amello Jason · CIK 0001451805 · SVP, CFO & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131,766 F1 · shares: The restricted stock units were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended. One third of the restricted stock units will vest on each of the first, second and third anniversaries of the grant date. F2 · balance_after: Includes 265 shares of the Issuer's common stock purchased under the Issuer's 2014 Employee Stock Purchase Plan on December 31, 2018. Read SEC document |
| February 01, 2019 Filed Feb 5, 2019 13:47 UTC | Acer Therapeutics Inc. ACER · Entity 108116 | GrantEmployee Stock Option (right to buy) · Derivative | 6,000 | $0.00 Strike: $24.46 | $0.00 |
DisclosureSEC source: 0001209191-19-007236 · doc4.xml · derivative · entry 1 Amello Jason · CIK 0001451805 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires 2029-02-01 F1 · derivative.exercise_date: The option vests and becomes exercisable in full on February 1, 2020. Read SEC document |
| December 12, 2018 Filed Dec 13, 2018 08:08 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | Tax withholdingCommon Stock | 22,235 | $8.94 | $198,780.90 |
DisclosureSEC source: 0000899243-18-030789 · doc4.xml · nonDerivative · entry 1 Amello Jason · CIK 0001451805 · SVP, CFO & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,501 F1 · balance_after: Includes 1,500 shares acquired under the Akebia Therapeutics, Inc. stock purchase plan on June 29, 2018. Read SEC document |
| February 28, 2018 Filed Mar 2, 2018 16:15 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantEmployee Stock Option (Right to buy) · Derivative | 27,700 | $0.00 Strike: $14.30 | $0.00 |
DisclosureSEC source: 0001562180-18-001383 · primarydocument.xml · derivative · entry 2 Amello Jason · CIK 0001451805 · SVP, CFO & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,700 Underlying: Common Stock · 27,700 shares Expires 2028-02-28 F3 · derivative.exercise_date: The options were granted by the Issuer pursuant to its 2014 Incentive Plan. 25% of the shares underlying this option will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter. Read SEC document |
| February 28, 2018 Filed Mar 2, 2018 16:15 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantCommon Stock | 19,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-18-001383 · primarydocument.xml · nonDerivative · entry 1 Amello Jason · CIK 0001451805 · SVP, CFO & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,236 F1 · shares: The restricted stock units were granted by the Issuer pursuant to its 2014 Incentive Plan. One hundred percent of the restricted stock units will vest on the third anniversary of the grant date. F2 · balance_after: The total amount of beneficial securities owned includes 1,376 shares of stock purchased on June 30, 2017 at $8.92 per share and 723 shares of stock purchased on December 31, 2017 at $12.39 per share in connection with the Issuer's Employee Stock Purchase Plan. Read SEC document |
| October 04, 2017 Filed Oct 6, 2017 16:10 UTC | Acer Therapeutics Inc. ACER · Entity 108116 | GrantStock Option (right to buy) · Derivative | 9,000 | $0.00 Strike: $15.34 | $0.00 |
DisclosureSEC source: 0001654954-17-009221 · section16.xml · derivative · entry 1 Amello Jason · CIK 0001451805 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Stock · 9,000 shares Expires 2027-10-04 F1 · derivative.exercise_date: The option vests and becomes exercisable in twelve equal quarterly installments beginning on October 4, 2017. Read SEC document |
| February 21, 2017 Filed Feb 23, 2017 16:01 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantStock Option (Right to buy) · Derivative | 47,500 | $10.14 Strike: $0.00 | $481,650.00 |
DisclosureSEC source: 0001562180-17-000878 · primarydocument.xml · derivative · entry 2 Amello Jason · CIK 0001451805 · SVP, CFO & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,500 Underlying: Common Stock · 47,500 shares Expires 2027-02-21 F3 · derivative.exercise_date: 25% of the shares underlying this option will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter. Read SEC document |
| February 21, 2017 Filed Feb 23, 2017 16:01 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantCommon Stock | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-17-000878 · primarydocument.xml · nonDerivative · entry 1 Amello Jason · CIK 0001451805 · SVP, CFO & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,637 F1 · shares: The restricted stock units were granted by the Issuer pursuant to its 2014 Incentive Plan. One hundred percent of the restricted stock units will vest on the third anniversary of the grant date. F2 · balance_after: The total amount of beneficial securities owned includes 1,500 shares of stock purchased on June 30, 2016 at $6.35 per share and 807 shares of stock purchased on December 31, 2016 at $6.48 per share in connection with the Issuer's Employee Stock Purchase Plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.